Changes (paired) in patient outcomes following treatment switching to sacubitril/valsartan
| n | Pre-switching | Post-switching | Mean difference (SD) | 95% CI | P value | |
| SBP (mm Hg) | 68 | 123 | 112 | −10 (14) | −14 to −7 | <0.001 |
| DBP (mm Hg) | 68 | 72 | 68 | −4 (10) | −6 to −1 | 0.004 |
| NYHA score | 71 | 2.3 | 1.9 | −0.4 (0.63) | −0.6 to −0.2 | <0.001 |
| MLHFQ score | 33 | 46 | 38 | −9 (19) | −15 to −2 | 0.016 |
| LVEF (%) | 49 | 26 | 33 | 7 (10) | 4 to 10 | <0.001 |
| LVESD (cm) | 37 | 5.2 | 4.9 | - 0.3 (0.8) | −0.6 to −0.08 | 0.013 |
| LVEDD (cm) | 48 | 6.0 | 5.7 | −0.3 (0.7) | −0.5 to −0.1 | 0.042 |
| K+ (mmol/L) | 71 | 4.6 | 4.7 | 0.1 (0.40) | −0.01 to 0.20 | 0.054 |
| Creatinine (μmol/L) | 71 | 95 | 97 | 2 (14) | −1 to 6 | 0.17 |
| eGFR (mL/min/1.73 m2) | 71 | 69 | 67 | - 2 (13) | −5 to 1 | 0.23 |
DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; K+, potassium; LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end systolic diameter; MLHFQ, Minnesota Living with Heart Failure Questionnaire; NYHA, New York Heart Association; SBP, systolic blood pressure.